Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Concizumab plasma concentration measurements for personalized dose adjustment in patients with Hemophilia A/B with and without inhibitors: Data from the Phase 3 explorer7 and explorer8 studies

Hermann Eichler, Chris Barnes, Johnny Mahlangu, Mary Mathias, Jakob Oemar Gjørret, Thomas Porstmann, Tulika Seth, Sonata Šaulytė Trakymienė

Blood (2025) 146 (Supplement 1): 3070.

https://doi.org/10.1182/blood-2025-3070

Published: 2025

Journal Articles

Using FXIa-triggered thrombin generation to assess the risk of breakthrough bleeding in patients receiving emicizumab for acquired Hemophilia A

Fabius Pelzer, Ella Ertekin, Olga Oleshko, Annika Klingberg, Paul Knoebl, Christian Pfrepper, Richard Greil, Johannes Oldenburg, Ulrich Sachs, Wolfgang Miesbach, Karolin Trautmann-Grill, Katharina Holstein, Hermann Eichler, Patrick Moehnle, Christina Hart, Robert Klamroth, Andreas Tiede, Sonja Werwitzke

Blood (2025) 146 (Supplement 1): 310.

https://doi.org/10.1182/blood-2025-310

Published: 2025

Journal Articles

Concizumab efficacy in patients with Hemophilia A/B without inhibitors from the Phase 3 explorer8 study: A post-hoc sensitivity analysis for the intra-patient comparison of concizumab with previous prophylaxis

Anthony Chan, Hermann Eichler, Julien Bovet, Renée Brown Frandsen, Allison Wheeler, Pratima Chowdary

Blood (2025) 146 (Supplement 1): 1288.

https://doi.org/10.1182/blood-2025-1288

Published: 2025

Journal Articles

Fibroblast-activating protein as a biomarker for blood-induced joint inflammation in hemophilia

Lynn Knowles, Lisa Laux, Constantin Lapa, Michael Menger, Matthias Laschke, Hermann Eichler, Jan Pilch

Blood (2025) 146 (Supplement 1): 1280.

https://doi.org/10.1182/blood-2025-1280

Published: 2025

Journal Articles

Emicizumab Versus Immunosuppression for Acquired Hemophilia Α (AHA)

Christina Hart, Robert Klamroth, Ulrich J. Sachs, Richard Greil, Paul N. Knoebl, Johannes Oldenburg, Wolfgang Miesbach, Christian Pfrepper, Karolin Trautmann-Grill, Isabell Pekrul, Katharina Holstein, Hermann Eichler, Carmen Weigt, Dorothea Schipp, Sonja Werwitzke, Andreas Tiede

Blood (2023) 142 (Supplement 1): 2612.

https://doi.org/10.1182/blood-2023-174958

Published: 2023

Journal Articles

Efficacy and Safety of Concizumab Prophylaxis in Patients with Hemophilia A or B without Inhibitors: 56-Week Cut-Off Results of the Phase 3 explorer8 Study

Jan Astermark, Shashikant Apte, Chuhl Joo Lyu, Amalie Rhode Høgh Nielsen, Sonata Saulyte Trakymiene, Jay Jay Thaung Zaw, Huyen Tran, Jerzy Windyga, Hermann Eichler

Blood (2023) 142 (Supplement 1): 2609.

https://doi.org/10.1182/blood-2023-173118

Published: 2023

Journal Articles

Blood-Induced Inflammation in Hemophilia

Lynn M Knowles, Carolin Wolter, Michael D. Menger, Matthias W. Laschke, Felix Haegele, Hermann Eichler, Jan Pilch

Blood (2022) 140 (Supplement 1): 2707.

https://doi.org/10.1182/blood-2022-170235

Published: 2022

Journal Articles

Surgeries and Diagnostic Procedures in Hemophilia Patients on Concizumab Prophylaxis: Results from the Phase 2 Explorer4 and Explorer5 Trials

Allison P. Wheeler, Gary Benson, Hermann Eichler, Sidsel Marie Tønder, Katarina Cepo, Victor Jimenez Yuste, Kaan Kavakli, Lily LL Wong, Tadashi Matsushita

Blood (2021) 138 (Supplement 1): 345.

https://doi.org/10.1182/blood-2021-148571

Published: 2021

Journal Articles

First-in-Human Dose-Finding Study of AAVhu37 Vector-Based Gene Therapy: BAY 2599023 Has Stable and Sustained Expression of FVIII over 2 Years

Steven W Pipe, John P Sheehan, Michiel Coppens, Hermann Eichler, Camila Linardi, Sara Wiegmann, Charles RM Hay, Toshko Lissitchkov

Blood (2021) 138 (Supplement 1): 3971.

https://doi.org/10.1182/blood-2021-148661

Published: 2021

Journal Articles

Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study

Katharina Holstein, Xiaofei Liu, Andrea Smith, Paul Knöbl, Robert Klamroth, Ulrich Geisen, Hermann Eichler, Wolfgang Miesbach, Andreas Tiede

Blood (2020) 136 (3): 279–287.

https://doi.org/10.1182/blood.2019003639

Published: 2020

Includes: Supplemental data

Journal Articles

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results

Amy D. Shapiro, Pantep Angchaisuksiri, Jan Astermark, Gary Benson, Giancarlo Castaman, Pratima Chowdary, Hermann Eichler, Victor Jiménez-Yuste, Kaan Kavakli, Tadashi Matsushita, Lone Hvitfeldt Poulsen, Allison P. Wheeler, Guy Young, Silva Zupancic-Salek, Johannes Oldenburg

Blood (2019) 134 (22): 1973–1982.

https://doi.org/10.1182/blood.2019001542

Published: 2019

Includes: Multimedia, Supplemental data

Journal Articles

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

Hermann Eichler, Pantep Angchaisuksiri, MD, Jan Astermark, MD PhD, Gary Benson, Katarina Cepo, Pratima Chowdary, MD, Ute Friedrich, PhD, Kaan Kavakli, Allison P Wheeler, MD, Johannes Oldenburg, MD PhD

Blood (2019) 134 (Supplement_1): 2417.

https://doi.org/10.1182/blood-2019-122300

Published: 2019

Journal Articles

Low-Grade Inflammation in Hemophilia

Lynn M Knowles, PhD, Hermann Eichler, Jan Pilch, MD

Blood (2019) 134 (Supplement_1): 1115.

https://doi.org/10.1182/blood-2019-125127

Published: 2019

Journal Articles

Fibrin As a Target for Glioblastoma Detection and Treatment

Lynn M Knowles, PhD, Carolin Wolter, MS, Ralf Ketter, MD, Steffi Urbschat, PhD, Stefan Linsler, MD, Simon Müller, MD, Andreas Müller, PhD, Hermann Eichler, Jan Pilch, MD

Blood (2019) 134 (Supplement_1): 3630.

https://doi.org/10.1182/blood-2019-124089

Published: 2019

Journal Articles

Macrophage Polarization Is Impaired in Hemophilia

Lynn M Knowles, PhD, Daniela Lessig, Martin Bernard, Eva C Schwarz, PhD, Hermann Eichler, MD, Jan Pilch, MD

Blood (2018) 132 (Supplement 1): 2499.

https://doi.org/10.1182/blood-2018-99-117111

Published: 2018

Journal Articles

CLIC1 Cooperates with Integrins to Promote Thrombus Formation and Angiogenesis

Lynn M Knowles, PhD, Emmanuel Ampofo, PhD, Michael D Menger, MD, Patrick Niewald, Anna Drawz, Hermann Eichler, MD, Jan Pilch, MD

Blood (2018) 132 (Supplement 1): 2419.

https://doi.org/10.1182/blood-2018-99-119290

Published: 2018

Journal Articles

Factor VIII Activity and Risk of Bleeding in Acquired Hemophilia a: Results from the Gth-AH 01/2010 Study

Katharina Holstein, MD, Andrea Smith, Paul Knöbl, MD PhD, Christiane Dobbelstein, MD, Wolfgang A. Miesbach, MD PhD, Michael Spannagl, MD PhD, Jürgen Heinz, MD PhD, Ute Scholz, MD, Hermann Eichler, MD, Angela Huth-Kühne, MD, Robert Klamroth, MD PhD, Armin Koch, MD PhD, Andreas Tiede, MD

Blood (2017) 130 (Supplement 1): 22.

https://doi.org/10.1182/blood.V130.Suppl_1.22.22

Published: 2017

Journal Articles

Concizumab (Anti-TFPI) Exposure-Response Modeling in Patients with Hemophilia A

Hermann Eichler, MD, Pantep Angchaisuksiri, MD, Kaan Kavakli, MD, Paul Knöbl, MD PhD, Jerzy Windyga, Victor Jimenez-Yuste, Ute Friedrich, PhD, Philip Delff Andersen, Pratima Chowdary

Blood (2017) 130 (Supplement 1): 3672.

https://doi.org/10.1182/blood.V130.Suppl_1.3672.3672

Published: 2017

Journal Articles

Diagnostic and Prognostic Value of Factor VIII Binding Antibodies in Acquired Hemophilia A: Data from the GTH-AH 01/2010 Study

Andreas Tiede, MD PhD, Sonja Werwitzke, MD PhD, Ulrich Geisen, MD PhD, Ulrike Nowak-Göttl, MD PhD, Hermann Eichler, MD PhD, Bernhard Stephan, MD, Ute Scholz, MD, Holstein Katharina, MD, Robert Klamroth, Paul Knöbl, MD PhD, Angela Huth-Kühne, MD, Barbara Bomke, MD

Blood (2015) 126 (23): 3515.

https://doi.org/10.1182/blood.V126.23.3515.3515

Published: 2015

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Concizumab plasma concentration measurements for personalized dose adjustment in patients with Hemophilia A/B with and without inhibitors: Data from the Phase 3 explorer7 and explorer8 studies

Using FXIa-triggered thrombin generation to assess the risk of breakthrough bleeding in patients receiving emicizumab for acquired Hemophilia A

Concizumab efficacy in patients with Hemophilia A/B without inhibitors from the Phase 3 explorer8 study: A post-hoc sensitivity analysis for the intra-patient comparison of concizumab with previous prophylaxis

Fibroblast-activating protein as a biomarker for blood-induced joint inflammation in hemophilia

Emicizumab Versus Immunosuppression for Acquired Hemophilia Α (AHA)

Efficacy and Safety of Concizumab Prophylaxis in Patients with Hemophilia A or B without Inhibitors: 56-Week Cut-Off Results of the Phase 3 explorer8 Study

Blood-Induced Inflammation in Hemophilia

Surgeries and Diagnostic Procedures in Hemophilia Patients on Concizumab Prophylaxis: Results from the Phase 2 Explorer4 and Explorer5 Trials

First-in-Human Dose-Finding Study of AAVhu37 Vector-Based Gene Therapy: BAY 2599023 Has Stable and Sustained Expression of FVIII over 2 Years

Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

Low-Grade Inflammation in Hemophilia

Fibrin As a Target for Glioblastoma Detection and Treatment

Macrophage Polarization Is Impaired in Hemophilia

CLIC1 Cooperates with Integrins to Promote Thrombus Formation and Angiogenesis

Factor VIII Activity and Risk of Bleeding in Acquired Hemophilia a: Results from the Gth-AH 01/2010 Study

Concizumab (Anti-TFPI) Exposure-Response Modeling in Patients with Hemophilia A

Diagnostic and Prognostic Value of Factor VIII Binding Antibodies in Acquired Hemophilia A: Data from the GTH-AH 01/2010 Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only